What Tuteur Group does

Tuteur Group (legal entity Tuteur S.A.C.I.F.I.A.) is an Argentine pharmaceutical laboratory founded in 1972 in Luján, Buenos Aires, that develops, manufactures, and commercializes specialty pharmaceutical products for high-complexity and rare diseases. The company operates two cGMP-compliant production plants in Argentina — the original Luján site and a segregated oral solid dose plant inaugurated in Buenos Aires in 2012, supplemented by the Victoria non-segregated plant acquired in 2019 — totaling 7,500 square meters of production capacity. Its 140-product portfolio spans oncology, neurology, nephrology, autoimmune, biotherapeutic, pulmonology, hematology, and rare diseases, with a stated emphasis on orphan and low-incidence conditions.

Tuteur commercializes products through a sales-led, enterprise field model with direct commercial operations across 9 Latin American countries and export relationships into Europe (active since 1980). The Medical Science Liaison (MSL) team supports physicians with scientific collaboration and access facilitation, while the Programa Puentes patient support program provides direct engagement with patients on Tuteur therapies. A track-and-trace order platform serves institutional clients.

The company is family-controlled into its third generation of pharmacists, led by President Jonathan Hahn, and became fully independent in 2011 after acquiring Teva Pharmaceutical Industries' stake in the former Teva-Tuteur joint venture (formed 1992). With approximately 700 employees and an average of 55 new product registrations annually across Latin American regulatory regimes, Tuteur positions itself as a regional pioneer in rare-disease specialty pharmaceuticals.

Name

Tuteur Group

Legal name

Tuteur S.A.C.I.F.I.A.

Website

https://tuteurgroup.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

251–500 employees

Short description

Tuteur Group is an Argentine pharmaceutical laboratory founded in 1972 that manufactures and distributes a 140-product specialty portfolio for high-complexity and rare diseases across 9 Latin American countries, operating two cGMP plants in Argentina.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industry

Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals (HLAIAJAL)

Keywords

• Specialty pharmaceuticals
• Rare disease therapeutics
• Oncology medications
• Pharmaceutical manufacturing
• CGMP drug production

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Development, elaboration and commercialization of pharmaceutical products across Latin America and the world, focusing on high complexity diseases.
2. Medical Food Products: Commercialization of foods for specific medical purposes.
3. Food Industry Inputs: Commercialization and distribution of inputs for the food industry from international companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Tuteur Group develops, manufactures, and commercializes specialty pharmaceutical products targeting high-complexity and rare diseases — including oncology, neurology, nephrology, autoimmune, hematology, and orphan disease therapeutics. The company operates two cGMP-compliant manufacturing plants in Argentina and distributes its 140-product portfolio through its own commercial offices in 9 Latin American countries plus international export channels. It supplements product sales with patient support (Programa Puentes), physician scientific liaison services (MSL), and digital order tracking.

Product overview

Tuteur Group is a pharmaceutical laboratory with over 50 years of experience specializing in the development, production, and commercialization of pharmaceutical products for high-complexity diseases. The company operates two production plants in Argentina and distributes products across Latin America. The product portfolio is organized into therapeutic categories including: Oncology (with 40+ products such as ZANTERIB®/Cabozantinib, PACLITAXEL TUTEUR®, METAPLATIN®/Oxaliplatino), Neurology (with products like TILMURATO®/Dimetilfumarato, OSPOLOT®/Sultiame, KYMONOD®/Siponimod), Nephrology (including TOLKISTAN®/Tolvaptan, TENALCET®/Cinacalcet, FOSEVA®/Sevelamer Carbonato), and Rare Diseases (such as ORPHACOL®/Ácido Cólico, CARBAGLU®). The company also provides patient support services through its Programa Puentes, Medical Science Liaison (MSL) services, and a customer order tracking system. With 140 products in portfolio, 700 collaborators, and operations in 9 Latin American countries, Tuteur positions itself as a pioneer in rare and high-complexity diseases, offering both specialized pharmaceuticals and patient support services.

Differentiator

Problem solved

Functional benefit

Products and services

• AGACEL® (Imatinib) Oncology medication for the treatment of malignancies including chronic myeloid leukemia. Targeted at specialist oncologists and healthcare providers treating leukemia patients.
• ZANTERIB® (Cabozantinib)

Quantifiable outcome

• 140 products in portfolio across Latin America
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered major and minor.

• Teva Pharmaceutical IndustriesmajorStrategic or Co-development Partner · 1 January 1992Joint venture Teva-Tuteur established in 1992 with Teva, the world's largest generic pharmaceutical company. In 2011, Tuteur acquired Teva's participation to become 100% Tuteur. The partnership enabled market expansion and technology transfer in generic pharmaceuticals.
• International Food Industry SuppliersminorOthersCommercialization and distribution of inputs for the food industry from international companies, including dairy and wine industry products.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Gador: Argentine pharmaceutical laboratory with proprietary manufacturing and a specialty pharma portfolio spanning oncology, neurology, and other high-complexity areas. Comparable size and Latin American orientation to Tuteur.
• Laboratorios Roemmers: Large Argentine pharmaceutical group with proprietary manufacturing and broad specialty prescription portfolio across LATAM. Direct peer on Argentine-pharma-specialty axis with similar 9-country-ish reach.
• Laboratorios Casasco: Argentine pharmaceutical laboratory with specialty prescription focus across therapeutic categories, including central nervous system and oncology. Comparable Argentine specialty-pharma footprint.
• Laboratorio Raffo: Argentine specialty pharma with own manufacturing and oncology, neurology and rare-disease presence in LATAM. Closely comparable business model and therapeutic mix to Tuteur.
• Laboratorios Bagó: Argentine-headquartered specialty pharmaceutical group with manufacturing and broad LATAM distribution across therapeutic areas including oncology, neurology, and rare diseases. Closest comparable in scale, geography, and therapeutic mix to Tuteur Group.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical company and former JV partner of Tuteur (Teva-Tuteur, 1992–2011). Competes head-to-head in generic oncology, neurology, and nephrology molecules in LATAM.
• Eurofarma Laboratórios: Largest Brazilian-owned pharmaceutical company with own cGMP manufacturing, broad specialty and generic portfolio, and presence across LATAM. Larger and broader incumbent operating in overlapping specialty and rare-disease segments.
• Sandoz (Novartis): Global generic and biosimilar leader with significant LATAM presence. Directly competes with Tuteur's generic oncology and specialty molecules across the region.
• Aché Laboratórios: Major Brazilian pharmaceutical company with own manufacturing, oncology and specialty prescription products, and regional LATAM reach. Larger-scale LATAM specialty pharma comparable to Tuteur.

Emerging players

• Biopas: LATAM-focused specialty pharma with presence in rare diseases, specialty therapeutics, and biopharmaceuticals across multiple Latin American markets. Comparable emerging regional player targeting similar specialty/rare-disease positioning.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tuteur

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tuteur Group